Relapsed Marginal Zone Lymphoma

Drug	Drug Name	Drug Description
DB15035	Zanubrutinib	A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy.

Drug	Drug Name	Target	Type
DB15035	Zanubrutinib	Cytochrome P450 3A4	enzyme
DB15035	Zanubrutinib	P-glycoprotein 1	transporter
DB15035	Zanubrutinib	Cytochrome P450 2B6	enzyme
DB15035	Zanubrutinib	Tyrosine-protein kinase BTK	target
DB15035	Zanubrutinib	Epidermal growth factor receptor	target
DB15035	Zanubrutinib	Receptor tyrosine-protein kinase erbB-2	target
DB15035	Zanubrutinib	Receptor tyrosine-protein kinase erbB-4	target
DB15035	Zanubrutinib	Tyrosine-protein kinase ITK/TSK	target
DB15035	Zanubrutinib	Cytoplasmic tyrosine-protein kinase BMX	target
DB15035	Zanubrutinib	Tyrosine-protein kinase JAK2	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Tec	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Blk	target
DB15035	Zanubrutinib	Tyrosine-protein kinase JAK3	target
DB15035	Zanubrutinib	Protein-tyrosine kinase 6	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Fgr	target
DB15035	Zanubrutinib	Tyrosine-protein kinase FRK	target
DB15035	Zanubrutinib	Tyrosine-protein kinase Lck	target
DB15035	Zanubrutinib	Tyrosine-protein kinase TXK	target
DB15035	Zanubrutinib	Cytochrome P450 3A Subfamily	enzyme

Drug	Drug Name	Phase	Status	Count